China Biopharmaceuticals Limited (“China Biopharmaceuticals”) will hold its Annual General Meeting on June 5, 2024. The meeting will adopt a hybrid format of both physical and online virtual meetings. The General Meeting will discuss motions including general mandates to issue and repurchase shares, re-election of directors. In addition, the Company will offer share issuance and share repurchase authorization at the General Meeting and propose the re-election of Mr. Tse Ping, Mr. Luk Ching-fei and Mr. Li Tai Kui as directors. Shareholders will approve the consolidated financial statements, board reports and independent auditor's report for the year ended December 31, 2023 and decide whether to distribute a final dividend. The Company issued a Circular on 29 April 2024 detailing the meeting arrangements and the various motions. If shareholders are unable to attend in person, they may be instructed to appoint representatives to attend and vote in accordance with the Proxy Form.

China Biopharmaceuticals Limited (“China Biopharmaceuticals”) will hold its Annual General Meeting on June 5, 2024. The meeting will adopt a hybrid format of both physical and online virtual meetings. The General Meeting will discuss motions including general mandates to issue and repurchase shares, re-election of directors. In addition, the Company will offer share issuance and share repurchase authorization at the General Meeting and propose the re-election of Mr. Tse Ping, Mr. Luk Ching-fei and Mr. Li Tai Kui as directors. Shareholders will approve the consolidated financial statements, board reports and independent auditor's report for the year ended December 31, 2023 and decide whether to distribute a final dividend. The Company issued a Circular on 29 April 2024 detailing the meeting arrangements and the various motions. If shareholders are unable to attend in person, they may be instructed to appoint representatives to attend and vote in accordance with the Proxy Form.